Rejuvenate Biomed is a clinical-stage biotech company focused on repurposing approved drugs to develop therapeutics that delay the onset of age-related diseases, such as sarcopenia in older adults. Their ongoing Phase 2 clinical trial for RJx-01 aims to maintain muscle integrity in patients with COPD-related sarcopenia, addressing the significant decline in muscle strength and function associated with aging.
Funding
$18.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sarcopenia, characterized by age-related decline in muscle mass and function, significantly impacts older adults, especially those with chronic conditions like COPD. Current treatments are limited, leaving a substantial unmet need for effective therapies to maintain muscle integrity and improve quality of life in this population.
Solution
Rejuvenate Biomed is developing RJx-01, a repurposed drug, to address sarcopenia in older adults, particularly those with COPD. RJx-01 is currently undergoing a Phase 2 clinical trial to evaluate its potential to maintain muscle integrity in patients experiencing severe acute exacerbation of COPD. The company is also leveraging AI to accelerate its drug development pipeline for age-related diseases, aiming to discover and develop therapeutics that delay the onset of these conditions.
Target Audience
The primary target audience includes older adults suffering from sarcopenia, particularly those with COPD, as well as healthcare providers specializing in geriatric care and respiratory diseases.
Features
- RJx-01: A repurposed drug candidate targeting sarcopenia.
- Phase 2 clinical trial: Evaluating RJx-01's efficacy in maintaining muscle integrity in COPD patients.
- AI-driven drug repurposing: Utilizing artificial intelligence to identify and develop new treatments for age-related diseases.
- Focus on muscle strength, function, and fatigue resistance improvements.